|
| Status |
Public on Dec 01, 2020 |
| Title |
Selective lymphoma cell killing by a PRC2 small molecule inhibitor (ChIP-Seq set 2) |
| Organism |
Homo sapiens |
| Experiment type |
Genome binding/occupancy profiling by high throughput sequencing
|
| Summary |
Genome-wide distribution of EZH2, H3K27me3 and H3K36me1 determined by ChIP-seq in SUDHL6 cells in the absence or presence of iEZH
|
| |
|
| Overall design |
Histone marks (H3K27me3, H3K36me1) and EZH2 binding by ChIP-seq in SUDHL6 DLBCL cell line after 96 hours of treatment with iEZH (1.5 uM).
|
| |
|
| Contributor(s) |
Trojer P, Garapaty S, Lan F, Hatton C, Bryant B |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| Submission date |
Aug 29, 2012 |
| Last update date |
Dec 01, 2020 |
| Contact name |
Barbara M Bryant |
| E-mail(s) |
barbara.bryant@constellationpharma.com
|
| Organization name |
Constellation Pharmaceuticals
|
| Street address |
215 First Street
|
| City |
Cambridge |
| State/province |
MA |
| ZIP/Postal code |
02142 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
|
| Samples (8)
|
|
| This SubSeries is part of SuperSeries: |
| GSE40476 |
Selective lymphoma cell killing by a PRC2 small molecule inhibitor |
|
| Relations |
| BioProject |
PRJNA174127 |
| SRA |
SRP015322 |
Less...
More...